Safety against nephrotoxicity in paclitaxel treatment: Oral nanocarrier as an effective tool in preclinical evaluation with marked in vivo antitumor activity

Choudhury H 1 , Gorain B 2 , Tekade RK 3 , Pandey M 4 , Karmakar S 5 , Pal TK 6

Affiliations 

  • 1 Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700032, India. Electronic address: HiraChoudhury@imu.edu.my
  • 2 Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700032, India; Faculty of Pharmacy, Lincoln University College, Petaling Jaya, Selangor, Kuala Lumpur, 47301, Malaysia
  • 3 National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad, Department of Pharmaceutics, Opposite Air Force Station, Palaj, Gandhinagar, 382355, Gujarat, India
  • 4 International Medical University, School of Pharmacy, Department of Pharmaceutical Technology, 57000, Kuala Lumpur, Malaysia
  • 5 Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700032, India
  • 6 Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700032, India. Electronic address: proftkpal@gmail.com
Regul Toxicol Pharmacol, 2017 Dec;91:179-189.
PMID: 29080846 DOI: 10.1016/j.yrtph.2017.10.023

Abstract

Oral paclitaxel (PTXL) formulations freed from cremophor® EL (CrEL) is always in utmost demand by the cancerous patients due to toxicities associated with the currently marketed formulation. In our previous investigation [Int. J. Pharm. 2014; 460:131], we have developed an oral oil based nanocarrier for the lipophilic drug, PTXL to target bioavailability issue and patient compliance. Here, we report in vivo antitumor activity and 28-day sub-chronic toxicity of the developed PTXL nanoemulsion. It was observed that the apoptotic potential of oral PTXL nanoemulsion significantly inhibited the growth of solid tumor (59.2 ± 7.17%; p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications